 |
|
|
|
|
To receive notification about press releases, register for updates
5/6/2008
Novacea to Host Conference Call to Discuss First Quarter 2008 Financial Results
5/6/2008
Novacea Receives Notification From Schering-Plough of Termination of Collaboration Agreement
3/17/2008
Novacea Reports Fourth Quarter and Year-End 2007 Financial Results
3/12/2008
Novacea to Present at Cowen and Company Healthcare Conference
2/28/2008
Frederick J. Ruegsegger Elected to Novacea's Board of Directors
2/15/2008
Novacea's Proof-of-Principle Study of AQ4N in Solid Tumors Published in Clinical Cancer Research
1/6/2008
Novacea Provides Corporate and Development Update
12/18/2007
Judith A. Hemberger Elected to Novacea's Board of Directors
11/27/2007
Novacea Appoints Edward Schnipper As New Chief Medical Officer
11/12/2007
Novacea Reports Third Quarter 2007 Financial Results
11/5/2007
Novacea Halts ASCENT-2 Trial in Advanced Prostate Cancer
10/31/2007
Novacea to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10/30/2007
Novacea Provides Update on Ascent-2 Protocol Amendment
10/18/2007
Novacea Announces Management Changes
10/11/2007
Novacea Initiates Phase 2 Trial of AQ4N in Acute Lymphoblastic Leukemia
9/26/2007
Novacea Initiates Phase 2 Trial of Asentar in Advanced Pancreatic Cancer
9/20/2007
Novacea Appoints John P. Walker As CEO
9/19/2007
Novacea to Webcast Presentation at the 2007 UBS Global Life Sciences Conference
9/6/2007
Novacea to Webcast Presentation at the Bear Stearns Healthcare Conference
8/31/2007
Novacea Announces Resignation of Two Board Members
8/14/2007
Novacea Reports Second Quarter 2007 Financial Results
8/7/2007
Novacea to Host Conference Call to Second Quarter Financial Results & Development Update
7/11/2007
Novacea Receives $60 Million Under Schering-Plough Agreement For Asentar
6/22/2007
Novacea Selected to Join Russell 3000 Index
6/20/2007
Novacea Presents Two Posters at Annual ASCO Meeting
5/30/2007
Novacea and Schering-Plough Enter Into Worldwide Development and Commercialization Agreement for Asentar, a Novel Treatment for Prostate Cancer
5/14/2007
Novacea Reports First Quarter 2007 Financial Results
5/14/2007
Novacea to Host Conference Call to Discuss 1Q Financial Results
4/19/2007
Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
4/17/2007
Novacea Presents New Evidence That Its AQ4N Prodrug Candidate Selectively Targets Oxygen-Starved Regions in Tumors
3/26/2007
Novacea Reports Fourth Quarter and Year End 2006 Financial Results
3/22/2007
Novacea to Present at Future Leaders in Biotech Conference
3/8/2007
Novacea to Present at the Cowen and Company 27th Annual Health Care Conference
2/20/2007
Novacea's ASCENT Phase 2 Trial Published in the Journal of Clinical Oncology
2/8/2007
Novacea to Present at BIO CEO Conference
12/11/2006
Novacea Announces Positive AQ4N Phase 1 Study in Lymphoma at ASH Annual Meeting
12/7/2006
Novacea Announces Resignation of Brad Goodwin as CEO
11/13/2006
Novacea Reports Third Quarter 2006 Financial Results
11/10/2006
Novacea Announces Updated AQ4N Phase 1 Data Presented at EORTC-NCI-AACR Symposium
11/2/2006
Novacea to Present at Upcoming Rodman & Renshaw and Cowen and Company Healthcare Conferences
11/1/2006
Novacea Initiates Phase 1/2 Trial of AQ4N in Glioblastoma Multiforme
11/1/2006
Novacea to Focus Development Attention and Resources on Oncology Product Candidates, Asentar and AQ4N
10/30/2006
Novacea's Phase 1 Data of Asentar Published in the Journal of Cancer Chemotherapy and Pharmacology
9/20/2006
British Journal Of Haematology Publishes Thrombosis Findings From ASCENT Trial
9/5/2006
Novacea to Present at Upcoming Newsmakers and Bear Stearns Investor Healthcare Conferences
8/11/2006
Novacea Reports Second Quarter 2006 Financial Results
8/2/2006
Novacea Appoints John P. Walker as Chairman of Board of Directors
6/14/2006
Novacea Appoints John Walker to Board of Directors
6/9/2006
Novacea Appoints Paul Laland as Vice President, Corporate Communications
6/8/2006
Novacea Announces Exercise Of Over-Allotment Option
6/8/2006
Novacea Announces Preliminary Results of a Phase 1/2 Clinical Trial in Non-Small Cell Lung Cancer
6/7/2006
Novacea to Present at the Pacific Growth Equities 2006 Life Sciences Growth Conference
6/5/2006
New Data Presented At ASCO Continue To Support Clinical Development Of Novacea’s Investigational Products
5/10/2006
Novacea Announces Initial Public Offering
4/12/2006
Novacea Initiates Pivotal Phase 3 Clinical Study of DN-101 in Men with Advanced Prostate Cancer
4/5/2006
Clinical and Preclinical Data on AQ4N (Banoxantrone) Presented at AACR
3/15/2006
Novacea Appoints Amar Singh as Chief Commercialization Officer
2/10/2006
Novacea Files For Initial Public Offering
1/4/2006
Novacea Raises Over $25 Million In Private Financing
11/11/2005
Novacea Announces Appointment Of Daniel M. Bradbury To Board Of Directors
11/2/2005
Novacea Announces Plans To Begin Phase 3 Clinical Study Of DN-101 In Prostate Cancer In First Quarter 2006
9/7/2005
The San Francisco 49ers and Novacea Join Forces to Tackle Prostate Cancer
9/7/2005
Novacea Announces Appointment Of Ivy Ang As Vice President, Human Resources
7/25/2005
Novacea And Pierre Fabre Medicament Enter Into Partnership For The Development And Commercialization Of Oral Vinorelbine For Oncology
7/20/2005
Novacea Expands Management Team with Key Appointments in Clinical Development, Regulatory Affairs and Business Development
5/15/2005
Novacea Announces Results from ASCENT Study of DN-101 at ASCO Today
4/27/2005
Novacea Announces ASCENT Clinical Trial Results, Including Survival Data, Will Be Presented At ASCO
4/20/2005
Novacea Begins Phase 1/2 Trial Of Anti-Cancer Agent Banoxantrone (AQ4N) In Patients With Lymphoma
4/15/2005
Novacea Announces Three Presentations On Anti-Cancer Agent, Banoxantrone (AQ4N), At AACR Meeting
4/5/2005
Novacea To Present At Future Leaders In Biotech Industry Conference
12/1/2004
Novacea to Present at 46th Annual American Society for Hematology Meeting
9/23/2004
Novacea Begins Phase 1 Dose Escalation Trial Of Anti-Cancer Agent AQ4N
-- Study Will Determine Safety and Tolerability of Multiple Weekly Doses in Patients With Advanced Malignancies --
8/4/2004
Novacea Provides Update on Phase 2/3 Clinical Trial of DN-101 Plus Taxotere in Advanced Prostate Cancer
6/7/2004
AQ4N Well Tolerated In First Phase I Report
3/30/2004
Novacea to Present at Future Leaders in Biotech Industry Conference
3/24/2004
Novacea Announces Several Presentations At Upcoming AACR Meeting
3/1/2004
Novacea Appoints Vice President And Chief Financial Officer
2/20/2004
Novacea To Present At The 6th Annual Bio Ceo & Investor Conference
1/22/2004
Novacea To Present At Piper Jaffray Healthcare Conference
1/8/2004
Novacea Raises $35 Million In Series C Round Led By Apax Partners
12/22/2003
Novacea Stops Enrollment In Trial Of DN-101 As Monotherapy In Myelodysplastic Syndromes
12/18/2003
Novacea Reaches Target Enrollment For Phase 2/3 Trial Studying DN-101, A Novel Prostate Cancer Therapy
12/11/2003
Novacea Licenses Novel Anti-Cancer Product Candidate From KuDOS Pharmaceuticals
8/18/2003
Novacea Begins Phase 1/2 Trial To Evaluate Impact Of DN-101 On Chemotherapy For Advanced Non-Small Cell Lung Cancer
3/18/2003
Oregon Health & Science University and Novacea Announce Broad Patent for Unique Formulation and Use of Vitamin D for Cancer Treatment
3/4/2003
Novacea Enhances Senior Management Team To Optimally Develop Lead Product And Guide Future Product Portfolio Strategy
1/15/2003
Novacea Begins Phase 2 Clinical Trial with DN-101 in MDS
1/15/2003
Novacea Appoints Robert L. Capizzi, MD, Vice President, Medical Affairs
11/4/2002
Novacea Raises $36 Million And Appoints Two New Board Members
9/18/2002
Novacea Announces Start Of Phase 2/3 Trial With DN-101 And Taxotere® In Advanced Prostate Cancer
9/18/2002
New Study Expands Look At Effects Of High-Dose Vitamin D With Docetaxel For Advanced Prostate Cancer Patients — Source: Oregon Health & Science University
9/16/2002
Novacea To Present At Bear Stearns 15th Annual Healthcare Conference
8/6/2002
Sunlight, a Cancer Protector in the Guise of a Villain? — Source: Centers for Disease Control
5/20/2002
Novacea Announces Progress with Lead Cancer Compound and Completion of Executive Management Team
5/18/2002
Study Shows Benefits of Adding High-Dose Vitamin D to Chemotherapy for Advanced Prostate Cancer — Source: Oregon Health & Science University
|
|
|
|
|
|
|
